Molecular Partners AG Announces New Preclinical Data at AACR 2025
Molecular Partners AG, a Swiss biotechnology company listed on the SIX Swiss Exchange, has recently presented new preclinical data on its Radio-DARPin and Switch-DARPin programs at the AACR 2025 conference. The company, which specializes in developing biopharmaceutical products using designed ankyrin repeat protein platform therapies, showcased significant advancements in its pipeline.
Key Developments:
Radio-DARPin Program: Molecular Partners presented positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3. This program is the most advanced in its class and is in co-development with Orano Med. Clinical development for MP0712 is set to commence in 2025.
Novel Targeted Radio-DARPin: The company also shared first preclinical data on a novel targeted Radio-DARPin against mesothelin (MSLN), which is being developed in collaboration with an undisclosed partner.
These developments highlight Molecular Partners’ commitment to advancing its therapeutic pipeline, particularly in oncology, where DLL3 and mesothelin are significant targets. The company’s focus on innovative protein platform therapies positions it as a key player in the biotechnology sector.
Company Overview:
- Sector: Health Care
- Industry: Biotechnology
- Primary Exchange: SIX Swiss Exchange
- Currency: CHF
- Close Price (2025-04-23): 3.47 CHF
- 52 Weeks High: 9.5 CHF (2024-06-18)
- 52 Weeks Low: 2.7 CHF (2025-04-06)
- Market Cap: 136,870,033 CHF
Molecular Partners AG serves healthcare professionals and patients globally, with a focus on ophthalmology, oncology, inflammation, and other therapeutic treatments. For more information, visit their website at www.molecularpartners.com .
These announcements are expected to positively impact the company’s market perception and investor confidence as it progresses towards clinical trials.